Alnylam Pharmaceuticals saw its stock price jump in morning trading, gaining 11.4% after rival Ionis Pharmaceuticals and its partner AstraZeneca disclosed that their Phase 3 CARDIO-TTRansform trial of eplontersen - marketed as Wainua - failed to achieve the study's primary efficacy endpoint in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
According to the companies, the trial missed its composite primary goal of reducing cardiovascular mortality and recurrent cardiovascular events over a 140-week period compared with placebo. The result surprised many on Wall Street, where success in the study had been broadly anticipated and had been viewed as a path to entering a market that analysts estimate could exceed $15 billion, a market where Alnylam’s AMVUTTRA (vutrisiran) is currently the leader.
Analysts were quick to re-evaluate the competitive dynamics. Stifel reiterated its Buy rating on Alnylam, noting that the negative outcome for eplontersen effectively removes a major valuation driver from Ionis’s model and further solidifies Alnylam’s position within the ATTR-CM treatment landscape. The commentary emphasized that the failed study outcome strengthens the case for Alnylam’s established RNA interference approach.
One particularly notable aspect of the CARDIO-TTRansform readout was that a majority of enrolled patients were already on transthyretin (TTR) stabilizer therapy at baseline. In that subgroup, adding eplontersen did not deliver a statistically significant benefit, underscoring the challenge of displacing therapies in a setting where incumbents or background regimens are already influencing outcomes.
Broader market conditions provided modest support on the session, with the S&P 500 up 0.2%, the Dow Jones Industrial Average up 0.1% and the Nasdaq Composite up 0.3%. Those market moves, however, were not the primary driver of Alnylam’s strong performance, which was rooted in the competitive implications of the trial failure.
Investor flows reflected the shifting conviction. BridgeBio Pharma also rallied sharply on the same competitive news, while Ionis shares plunged and AstraZeneca’s U.S.-listed shares fell meaningfully. The pattern of moves illustrated a rotation of investor capital toward beneficiaries of the trial result and away from the companies directly affected by the negative readout.
Taken together, the collapse of eplontersen’s ATTR-CM prospects delivered an unanticipated advantage to Alnylam, reinforcing its status as the leading RNAi developer in a fast-growing rare disease cardiology niche. With AMVUTTRA now facing reduced near-term competitive pressure and Alnylam’s stock still trading well below its 52-week high of $495.55, the early trading surge appears to reflect both relief and renewed investor optimism about the durability of the company’s franchise.
Key points
- Alnylam stock jumped 11.4% in morning trading after Ionis/AstraZeneca said the Phase 3 CARDIO-TTRansform trial of eplontersen failed to meet its primary endpoint in ATTR-CM.
- The failed trial removes a significant valuation driver from Ionis’s outlook and reduces near-term competitive pressure on Alnylam’s AMVUTTRA (vutrisiran), according to analysts such as Stifel.
- Market reaction included sharp rallies for some peers and steep declines for Ionis and AstraZeneca’s U.S.-listed shares, illustrating investor rotation within the biotech sector and related markets.
Risks and uncertainties
- The primary risk highlighted by the companies’ announcement is the uncertainty for Ionis and AstraZeneca’s eplontersen program following the Phase 3 failure in ATTR-CM, which directly impacts their prospects in the cardiology rare-disease market.
- Market volatility is a risk for investors, as the trial outcome prompted sharp moves across multiple biotech names, indicating sensitivity to single clinical-readout events within the sector.
- Despite today’s positive reaction for Alnylam, its shares remain below their 52-week high of $495.55, reflecting residual uncertainty about longer-term competitive dynamics and valuation.